Sage Therapeutics says rare disease drug found to be safe in mid-stage study
Updates shares in paragraph 4, adds details on trial in paragraphs 5 & 9, analysts comments in paragraphs 6, 8 & 10
June 11 (Reuters) -Sage Therapeutics SAGE.O said on Tuesday a part of a mid-stage study showed its experimental drug was safe and had some effect in patients with a rare, genetic neurological condition called Huntington's disease.
The company, however, said the study in Huntington's disease patients was not designed to show a statistically significant difference between the drug dalzanemdor and placebo.
The development comes on the back of a mid-stage trial failure for the same drug in April,when it was tested in patients with Parkinson's disease. Shares of Sage Therapeutics have fallen over 13% since then.
The stock, which soared 80% initially premarket, erased those gains and were down more than 3% in early trading.
There was a small numerical difference observed between dalzanemdor and placebo at day 28, on a set of tests which measures cognitive impact of the disease, the company said.
While it was good to note a directional positive change between treatment and placebo, "it is difficult to decipher how much one can read into the 28-day data," said Needham & Co analyst Ami Fadia.
The difference was measured by the HD-Cognitive Assessment Battery or HD-CAB, a composite of six individual tests to assess various domains of cognition relevant to disease.
William Blair analyst Tim Lugo said the study was "underwhelming" and it seemed that the assessment scale was more validated than the drug as it does not provide much data on the activity of dalzanemdor.
The small mid-stage study enrolled 40 patients with the disease and 29 healthy patients.
The two analysts said they were looking forward to data from a larger study, which will assess cognitive impairment over 12 weeks in 178 patients, and better ascertain the treatment's effect.
Reporting by Sriparna Roy in Bengaluru; Editing by Shailesh Kuber
Mga Kaugnay na Asset
Pinakabagong Balita
Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.
Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.
Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.
